Gui L, Zhu H, Tang L, Zhu Y, et al. Anlotinib Plus Sintilimab for BRAF(V600E) Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial. Thyroid 2026 Jan 24:10507256261416838. doi: 10.1177/10507256261416838.
PMID: 41579120